Literature DB >> 17182579

IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction.

Dorothée Missé1, Hans Yssel, Daria Trabattoni, Christelle Oblet, Sergio Lo Caputo, Francesco Mazzotta, Jérome Pène, Jean-Paul Gonzalez, Mario Clerici, Francisco Veas.   

Abstract

Certain individuals are resistant to HIV-1 infection, despite repeated exposure to the virus. Although protection against HIV-1 infection in a small proportion of Caucasian individuals is associated with mutant alleles of the CCR5 HIV-1 coreceptor, the molecular mechanism underlying resistance in repeatedly HIV-1-exposed, uninfected individuals (EU) is unclear. In this study, we performed complementary transcriptome and proteome analyses on peripheral blood T cells, and plasma or serum from EU, their HIV-1-infected sexual partners, and healthy controls, all expressing wild-type CCR5. We report that activated T cells from EU overproduce several proteins involved in the innate immunity response, principally those including high levels of peroxiredoxin II, a NK-enhancing factor possessing strong anti-HIV activity, and IL-22, a cytokine involved in the production of acute-phase proteins such as the acute-phase serum amyloid A (A-SAA). Cell supernatants and serum levels of these proteins were up-regulated in EU. Moreover, a specific biomarker for EU detected in plasma was identified as an 8.6-kDa A-SAA cleavage product. Incubation of in vitro-generated myeloid immature dendritic cells with A-SAA resulted in CCR5 phosphorylation, down-regulation of CCR5 expression, and strongly decreased susceptibility of these cells to in vitro infection with a primary HIV-1 isolate. Taken together, these results suggest new correlates of EU protection and identify a cascade involving IL-22 and the acute phase protein pathway that is associated with innate host resistance to HIV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17182579     DOI: 10.4049/jimmunol.178.1.407

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Acute HIV-1 seroconversion with an unusual plasma biomarker profile.

Authors:  Najib Aziz; Roger Detels; Otoniel Martinez-Maza; John Oishi; Beth D Jamieson; Mallory D Witt; Anthony W Butch
Journal:  Clin Vaccine Immunol       Date:  2013-09-04

2.  IL-22 suppresses HSV-2 replication in human cervical epithelial cells.

Authors:  Xi-Qiu Xu; Yu Liu; Biao Zhang; Hang Liu; Dan-Dan Shao; Jin-Biao Liu; Xu Wang; Li-Na Zhou; Wen-Hui Hu; Wen-Zhe Ho
Journal:  Cytokine       Date:  2019-07-22       Impact factor: 3.861

3.  Role of IL-6 in the resolution of pancreatitis in obese mice.

Authors:  Maria Pini; Davina H Rhodes; Karla J Castellanos; Andrew R Hall; Robert J Cabay; Rohini Chennuri; Eileen F Grady; Giamila Fantuzzi
Journal:  J Leukoc Biol       Date:  2012-03-16       Impact factor: 4.962

Review 4.  Biological and pathological activities of interleukin-22.

Authors:  Mirna Perusina Lanfranca; Yanwei Lin; Jingyuan Fang; Weiping Zou; Timothy Frankel
Journal:  J Mol Med (Berl)       Date:  2016-02-29       Impact factor: 4.599

5.  Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.

Authors:  Andrea R Stacey; Philip J Norris; Li Qin; Elizabeth A Haygreen; Elizabeth Taylor; John Heitman; Mila Lebedeva; Allan DeCamp; Dongfeng Li; Douglas Grove; Steven G Self; Persephone Borrow
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 6.  Regulation and function of proinflammatory TH17 cells.

Authors:  Gustavo J Martinez; Roza I Nurieva; Xuexian O Yang; Chen Dong
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

7.  Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Authors:  Amanda B Macedo; Camille L Novis; Caroline M De Assis; Eric S Sorensen; Paula Moszczynski; Szu-Han Huang; Yanqin Ren; Adam M Spivak; R Brad Jones; Vicente Planelles; Alberto Bosque
Journal:  JCI Insight       Date:  2018-10-04

8.  Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection.

Authors:  Holger B Kramer; Kerry J Lavender; Li Qin; Andrea R Stacey; Michael K P Liu; Katalin di Gleria; Alison Simmons; Nancy Gasper-Smith; Barton F Haynes; Andrew J McMichael; Persephone Borrow; Benedikt M Kessler
Journal:  PLoS Pathog       Date:  2010-05-06       Impact factor: 6.823

9.  High systemic levels of interleukin-10, interleukin-22 and C-reactive protein in Indian patients are associated with low in vitro replication of HIV-1 subtype C viruses.

Authors:  Juan F Arias; Reiko Nishihara; Manju Bala; Kazuyoshi Ikuta
Journal:  Retrovirology       Date:  2010-03-09       Impact factor: 4.602

10.  Interleukin 22 is a candidate gene for Tmevp3, a locus controlling Theiler's virus-induced neurological diseases.

Authors:  F Levillayer; M Mas; F Levi-Acobas; M Brahic; J F Bureau
Journal:  Genetics       Date:  2007-05-04       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.